Pharma's Market
SPECIAL REPORT
MOST SHARED
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Robo-Deal Is All About Lowering Mortgage Principal
- Fidelity: 401(k) Balances Little Changed Over 2011
- Top Fashion Stocks for 2012
- Options Trader Scores Big on Diamond Foods Selloff
- iPad 3, iTV and iPhone 5 Should Drive Apple to $665: Money Pros
- Chesapeake Spurs Nat Gas Rally
- FBI Investigated Steve Jobs Drug Use
- Can Anybody Be an Entrepreneur?
- 'Mortgage Deal from Hell' Hurts Responsible Borrowers: Bove
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- Robo-Deal Is All About Lowering Mortgage Principal
- Groupon Needs More Disclosure: Analyst
- CEO to CEO: Taking a Job at a Startup vs. a Public Company
- Farr: Money, Jobs and Politics — We're Still in a State of Risk
- Warren Buffett: Stocks Will Outperform Gold and Bonds
- 'Mortgage Deal from Hell' Hurts Sound Borrowers: Bove
- Fidelity: 401(k) Balances Little Changed Over 2011
- Are Young American Workers a 'Lost Generation'?
- 12 Unique Dating Sites
- Greek Political Leaders Agree On Austerity Reforms
- Robo-Deal Is All About Lowering Mortgage Principal
- Fed Fines Banks $766 Million Over Mortgage Practices
- Options Trader Scores Big on Diamond Foods Selloff
RSS FEED
Boston Scientific: Hurry To The Pre-4th of July Sale On Stents!?
Text Size 
Reporter
 |
Fourth of July fireworks |
Taxus is the name of Boston Scientific's [BSX
Loading...
()
] drug-coated stent, a tiny wire mesh cylinder that props open clogged arteries. This isn't all that surprising given the fact that Medtronic [MDT
Loading...
()
]recently entered the drug-coated stent market, busting up the duopoly of BSX and Johnson & Johnson[JNJ
Loading...
()
].
And any day now, there could be a fourth player. Some analysts still expect Abbott[ABT
Loading...
()
] to win Food and Drug Administration approval of its drug-coated stent Xience by the end of this month. But at least a couple of them, including FBR's Warren, now believe approval could come later rather than sooner. The analyst quotes an interventional cardiologist (the docs who put in stents) who says ABT's sales reps are telling him (the doc) that Xience will be launched in the fourth quarter.
JPMorgan's medical device guy Mike Weinstein emailed me to say that Abbott is apparently telling him to continue to look for approval here in Q2. Under the odd terms of BSX's acquisition of Guidant--it had to sell pieces of it to ABT--Boston Scientific would get to sell the Xience stent, but using the brand name Promus. Most analysts think Xience will quickly become the stent of choice because tests have shown it may have a lower rate of blood clots forming down the road and doctors think it's easier to put in.
Warren says his expert who works here in the New York area indicated that drug-coated stent prices have fallen 21 percent over the past year to the $1,100 BSX is charging in its bundling deal regardless of how many stents a cath lab (the highly profitable unit of a hospital where stent procedures are done) might buy. FBR makes a market in BSX.
I've left a landline and mobile voicemail and sent an email to BSX's main spokesman to try to confirm the FBR report. Usually I get a quick reply, but it's vacation season. And in the past the company hasn't commented outside of an earnings press release or conference call on current pricing.
UPDATE: So, I did hear back via email from BSX spokesman Paul Donovan who, as I suspected he would, wrote, "We typically don't comment on price beyond list price."
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
